Hemostatic therapy
| . | Before emicizumab . | After emicizumab . | ||
|---|---|---|---|---|
| Median . | IQR, range . | Median . | IQR, range . | |
| Hemostatic therapy | ||||
| Duration, d | 3 | 2-8, 0-13 | 1.5 | 0.8-4, 0-16 |
| APCC, ×1000 U | 0 | 0-15, 0-68 | 0 | 0-0, 0-0 |
| rhFVIIa for | ||||
| Active bleeding, mg | 55 | 34-128, 0-402 | 0 | 0-59, 0-224 |
| Prophylaxis, mg | 0 | 0-0, 0-54 | 2.5 | 0-35, 0-275 |
| FVIII concentrate | ||||
| Human, ×1000 U | 0 | 0-5, 0-130 | 0 | 0-0, 0-22 |
| Porcine, ×1000 U | 0 | 0-0, 0-3 | 0 | 0-0, 0-0 |
| RBC concentrates, U | 3 | 0-7, 0-20 | 0.7 | 0-0.5, 0-4 |
| . | Before emicizumab . | After emicizumab . | ||
|---|---|---|---|---|
| Median . | IQR, range . | Median . | IQR, range . | |
| Hemostatic therapy | ||||
| Duration, d | 3 | 2-8, 0-13 | 1.5 | 0.8-4, 0-16 |
| APCC, ×1000 U | 0 | 0-15, 0-68 | 0 | 0-0, 0-0 |
| rhFVIIa for | ||||
| Active bleeding, mg | 55 | 34-128, 0-402 | 0 | 0-59, 0-224 |
| Prophylaxis, mg | 0 | 0-0, 0-54 | 2.5 | 0-35, 0-275 |
| FVIII concentrate | ||||
| Human, ×1000 U | 0 | 0-5, 0-130 | 0 | 0-0, 0-22 |
| Porcine, ×1000 U | 0 | 0-0, 0-3 | 0 | 0-0, 0-0 |
| RBC concentrates, U | 3 | 0-7, 0-20 | 0.7 | 0-0.5, 0-4 |
Medians, IQR, and range; n = 12.
RBC, red blood cell; U, units.